Replies to post #173905 on Biotech Values

[DewDiligence]

ZSAR IPOs 5.2M* shares @$11.00:

http://finance.yahoo.com/news/zosano-pharma-announces-pricing-initial-132451802.html

Zosano Pharma Corporation is a clinical stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver its proprietary formulations of existing drugs through the skin for the treatment of a variety of indications. Zosano's microneedle patch system offers rapid onset, consistent drug delivery, improved ease of use and room-temperature stability, benefits that the company believes often are unavailable using oral formulations or injections… It has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies.

*Assuming exercise of underwriter’s option.

[DewDiligence]

EMIS +50%/NVO +5% on phase-2 results for oral GLP-1:

http://finance.yahoo.com/news/novo-nordisk-announces-positive-results-123700254.html

Novo Nordisk today announced that it has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks.

EMIS stands to earn an undisclosed (presumably single-digit) royalty on sales if this product is commercialized.